uridine has been researched along with denufosol tetrasodium in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (62.50) | 29.6817 |
| 2010's | 9 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, WM; Boucher, RC; Boyer, J; Cowlen, M; Davis, CW; Dougherty, R; Jones, AC; Lang-Furr, M; Picher, M; Sabater, JR; Stutts, MJ; Yerxa, BR | 1 |
| Blaug, SA; Jalickee, S; Maminishkis, A; Miller, SS; Peterson, WM; Rymer, J; Yerxa, BR | 1 |
| Hotta, K; Jaffe, GJ; Meyer, CH; Peterson, WM; Toth, CA | 1 |
| Evans, R; Kellerman, D; Mathews, D; Shaffer, C | 1 |
| Amar, T; Caillaud, T; Douglass, JG; Edick, C; Elena, PP; Peterson, WM; Yerxa, BR | 1 |
| Al-Ubaidi, MR; Naash, MI; Nour, M; Peterson, WM; Quiambao, AB | 1 |
| Daines, C; Deterding, R; Engels, J; Gibson, R; Gorden, J; Lavange, L; Marshall, B; Mathews, D; Milgram, L; Milla, C; Ramsey, B; Retsch-Bogart, G; Schaberg, A; Williams, J; Zeitlin, PL | 1 |
| Brody, AS; Coquillette, SJ; Deterding, RR; Engels, JM; Lavange, LM; Mathews, DW; Millard, SP; Ramsey, BW | 1 |
| Goss, CH; Kerr, D; Mathews, D; McKone, EF; Millard, SP; Wanger, JS | 1 |
| Farjo, R; Naash, MI; Peterson, WM | 1 |
| Engels, J; Gorden, J; Kellerman, D; Rossi Mospan, A; Schaberg, A; Smiley, L | 1 |
| Boucher, RC; Clunes, MT | 1 |
| Storey, S; Wald, G | 1 |
| Thompson, CA | 1 |
| Ratjen, F | 1 |
| Donaldson, SH; Paré, PD; Rosenfeld, M; Tiddens, HA | 1 |
| Davis, SD; Ferkol, TW | 1 |
| Accurso, FJ; Anbar, RD; Durham, TA; Moss, RB; Ramsey, BW; Schaberg, AE; Wilmott, RW | 1 |
| Sly, PD; Stick, SM | 1 |
| Accurso, FJ; Barnes, M; Durham, T; Moss, RB; Navratil, T; Ratjen, F; Schaberg, A; Wainwright, C | 1 |
| Moss, RB | 1 |
| Donaldson, SH; Galietta, L | 1 |
| Boucher, RC; Button, B; Frederick, CB; Okada, SF; Thelin, WR | 1 |
| Appy, L; Chardet, C; Peyrottes, S; Roy, B | 1 |
6 review(s) available for uridine and denufosol tetrasodium
| Article | Year |
|---|---|
Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease.
Topics: Administration, Inhalation; Animals; Clinical Trials as Topic; Cystic Fibrosis; Deoxycytosine Nucleotides; Epithelium; Humans; Mucociliary Clearance; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2Y2; Uracil Nucleotides; Uridine | 2002 |
Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3.
Topics: Administration, Inhalation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cystic Fibrosis; Deoxycytosine Nucleotides; Female; Forced Expiratory Volume; Humans; Male; Polyphosphates; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2Y2; Uracil Nucleotides; Uridine | 2008 |
Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Deoxycytosine Nucleotides; Humans; Ion Transport; Lung; Mannitol; Peptides, Cyclic; Saline Solution, Hypertonic; Sodium Channel Blockers; Uridine | 2008 |
Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?
Topics: Administration, Inhalation; Airway Obstruction; Airway Remodeling; Anti-Inflammatory Agents; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Deoxycytosine Nucleotides; Humans; Infant; Ion Transport; Mannitol; Mucociliary Clearance; Mucus; Neutrophils; Pneumonia, Bacterial; Pulmonary Alveoli; Radiography; Respiratory Mucosa; Sodium Channel Blockers; Uridine; Young Adult | 2010 |
New pulmonary therapies directed at targets other than CFTR.
Topics: Anoctamin-1; Bacteriocins; Chloride Channels; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Deoxycytosine Nucleotides; Diuretics, Osmotic; Epithelial Cells; Epithelial Sodium Channel Blockers; Epithelial Sodium Channels; Humans; Mannitol; Mucociliary Clearance; Neoplasm Proteins; Peptides; Sodium; Uridine | 2013 |
Synthetic Strategies for Dinucleotides Synthesis.
Topics: Deoxycytosine Nucleotides; Dinucleoside Phosphates; Dry Eye Syndromes; Green Chemistry Technology; Humans; Ophthalmic Solutions; Phosphorylation; Polyphosphates; Purinergic P2Y Receptor Agonists; Receptors, Purinergic; Uracil Nucleotides; Uridine | 2019 |
6 trial(s) available for uridine and denufosol tetrasodium
| Article | Year |
|---|---|
Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Child; Cystic Fibrosis; Deoxycytosine Nucleotides; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2Y2; Uridine | 2005 |
Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.
Topics: Adolescent; Adult; Child; Cough; Cystic Fibrosis; Deoxycytosine Nucleotides; Double-Blind Method; Female; Humans; Lung Volume Measurements; Male; Middle Aged; Nebulizers and Vaporizers; Purinergic P2 Receptor Agonists; Treatment Outcome; Uridine | 2007 |
Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Cystic Fibrosis; Deoxycytosine Nucleotides; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Maximal Expiratory Flow Rate; Severity of Illness Index; Spirometry; Treatment Outcome; Uridine; Vital Capacity | 2008 |
Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function.
Topics: Adolescent; Adult; Analysis of Variance; Child; Child, Preschool; Cystic Fibrosis; Deoxycytosine Nucleotides; Double-Blind Method; Female; Humans; Lung; Male; Respiratory Function Tests; Severity of Illness Index; Treatment Outcome; Uridine; Young Adult | 2011 |
Exciting new clinical trials in cystic fibrosis: infants need not apply.
Topics: Adult; Age Factors; Child, Preschool; Cystic Fibrosis; Deoxycytosine Nucleotides; Humans; Infant; Infant, Newborn; Lung; Uridine | 2011 |
Long term effects of denufosol tetrasodium in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Child; Child, Preschool; Chlorides; Cystic Fibrosis; Deoxycytosine Nucleotides; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Incidence; Kaplan-Meier Estimate; Lung; Lung Diseases; Male; Treatment Outcome; Uridine; Young Adult | 2012 |
12 other study(ies) available for uridine and denufosol tetrasodium
| Article | Year |
|---|---|
Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis.
Topics: Animals; Astrocytoma; Brain Neoplasms; Calcium; Chlorides; Cilia; Cystic Fibrosis; Deoxycytosine Nucleotides; Epithelial Cells; Humans; In Situ Hybridization; In Vitro Techniques; Indicators and Reagents; Macaca mulatta; Mucins; Mucociliary Clearance; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y2; Reverse Transcriptase Polymerase Chain Reaction; Sheep; Tumor Cells, Cultured; Uracil Nucleotides; Uridine | 2002 |
The P2Y(2) receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat.
Topics: Absorption; Animals; Biological Transport; Calcium; Cattle; Deoxycytosine Nucleotides; Electrophysiology; Humans; Injections; Ion Transport; Membrane Potentials; Pigment Epithelium of Eye; Purinergic P2 Receptor Agonists; Rats; Rats, Long-Evans; Receptors, Purinergic P2; Receptors, Purinergic P2Y2; Retinal Detachment; Uridine; Uridine Triphosphate; Vitreous Body; Water | 2002 |
Effect of INS37217, a P2Y(2) receptor agonist, on experimental retinal detachment and electroretinogram in adult rabbits.
Topics: Absorption; Animals; Body Fluids; Deoxycytosine Nucleotides; Disease Models, Animal; Electroretinography; In Situ Hybridization; Injections; Ophthalmoscopy; Pigment Epithelium of Eye; Purinergic P2 Receptor Agonists; Rabbits; Receptors, Purinergic P2; Receptors, Purinergic P2Y2; Retina; Retinal Detachment; RNA, Messenger; Tomography; Uridine | 2002 |
Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits.
Topics: Animals; Deoxycytosine Nucleotides; Eye; Male; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Rabbits; Tears; Uracil Nucleotides; Uridine | 2002 |
P2Y(2) receptor agonist INS37217 enhances functional recovery after detachment caused by subretinal injection in normal and rds mice.
Topics: Animals; Dark Adaptation; Deoxycytosine Nucleotides; Disease Models, Animal; DNA Fragmentation; Electroretinography; Female; Fluorescent Antibody Technique, Indirect; In Situ Nick-End Labeling; Injections; Mice; Mice, Inbred C57BL; Mice, Knockout; Microspheres; Photoreceptor Cells, Vertebrate; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2Y2; Recovery of Function; Retinal Detachment; Retinitis Pigmentosa; Uridine | 2003 |
Expression profiling after retinal detachment and reattachment: a possible role for aquaporin-0.
Topics: Animals; Aquaporins; Deoxycytosine Nucleotides; Disease Models, Animal; Electroretinography; Eye Proteins; Fluorescent Antibody Technique, Indirect; Gene Expression Profiling; Gene Expression Regulation; Immunoblotting; Immunoprecipitation; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Retinal Detachment; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation; Uridine | 2008 |
Novel agents in cystic fibrosis.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Deoxycytosine Nucleotides; Genetic Therapy; Humans; Mannitol; Natriuretic Agents; Osmolar Concentration; Uridine | 2008 |
Drug developers aim to treat cystic fibrosis through disease modification.
Topics: Administration, Inhalation; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Deoxycytosine Nucleotides; Genetic Therapy; Humans; Mutation; Oxadiazoles; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2Y2; Uridine | 2008 |
Update in cystic fibrosis 2008.
Topics: Amiloride; Animals; Bacterial Infections; Biomarkers; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Deoxycytosine Nucleotides; Disease Progression; Humans; Inflammation; Lung; Oxadiazoles; Respiratory Function Tests; Sodium Channel Blockers; Uridine | 2009 |
Hitting the target: new treatments for cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Deoxycytosine Nucleotides; Diuretics, Osmotic; Humans; Infant; Mannitol; Treatment Outcome; Uridine; Young Adult | 2010 |
Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis.
Topics: Adolescent; Alleles; Child; Child, Preschool; Clinical Trials as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Deoxycytosine Nucleotides; Disease Progression; Drug Design; Drug Industry; Female; Humans; Inflammation; Male; Research Design; Sputum; Time Factors; Treatment Outcome; Uridine | 2013 |
Mechanosensitive ATP release maintains proper mucus hydration of airways.
Topics: Adenosine; Adenosine Triphosphate; Cells, Cultured; Cilia; Deoxycytosine Nucleotides; Elasticity; Epithelial Cells; Epithelium; Extracellular Fluid; Humans; Intracellular Fluid; Microscopy, Confocal; Models, Biological; Mucociliary Clearance; Mucus; Purinergic P2Y Receptor Agonists; Receptors, Purinergic P2Y2; Respiratory Mucosa; Respiratory System; Stress, Mechanical; Uridine; Viscosity; Water | 2013 |